Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
AbbVie and Gedeon Richter join forces to advance neuropsychiatric target R&D
The companies will aim to discover and progress targets for neuropsychiatric disorders
Containment in a high potent manufacturing facility
Throughout the pharmaceutical industry, there is a lack of consistency regarding the assignment of Occupational Exposure Limits (OELs) to specific bands
Rousselot
Rousselot is the global leader* of collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical sectors. Working in partnership with our global...
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Causes and solutions for dark spots in tablet manufacturing
Natoli Engineering examines the causes and solutions for dark spots that can halt production
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Design & Build
GE Healthcare to open biotechnology manufacturing centre in UK
Located at the Stevenage Bioscience Catalyst, the facility includes 280sqm of cleanroom space
Research & Development
Consortium of UK Universities and global pharma companies launch £40m innovation fund
Apollo Therapeutics Fund will support translation of academic science into medicines for a broad range of diseases
Research & Development
Ian Tomlinson becomes Independent Chairman of Stevenage Bioscience Catalyst Board
Will guide open innovation campus in a phase of rapid development
Research & Development
Stevenage Bioscience Catalyst to fund six projects to fight neurodegenerative disease
Diverse players collaborate on first step in plan to tackle disorder through open innovation
Research & Development
New £55m cell therapy manufacturing centre to be built in Stevenage, UK
Will open in 2017 and create up to 150 jobs
Research & Development
GE Healthcare Life Sciences links up with Stevenage Bioscience Catalyst (SBC)
Joins neurodegenerative disease challenge and expands commitment to open innovation in healthcare
Research & Development
Stevenage Bioscience Catalyst gains £3m in funding
One tenant has also secured further funding, while another has extended its research collaborations
Subscribe now